Drugs / YUVA-GT-F901
last change Jun 2025 re-read 3 minutes ago

YUVA-GT-F901

targets F9

Developed for
hemophilia B
Investigated by
Shenzhen Geno-Immune Medical Institute

Trials 1

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03961243 Jun 2025 → May 2027 expected hemophilia B Shenzhen Geno-Immune Medical Institute Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as YUVA-GT-F901 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03961243 ↗
Target F9 “functional FIX gene” NCT03961243 ↗